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Abstract
Purpose: Many patients do not receive guideline-recom-
mended neoadjuvant chemoradiotherapy for resectable rectal
cancer. Little is known regarding long-term quality of life (QOL)
associated with various treatment approaches. Our objective
was to determine patient characteristics and subsequent QOL
associated with treatment approach.
Methods: Our study was a geographically diverse population- and
healthsystem–basedcohortstudy that includedadultsage21yearsor
older with newly diagnosed stage II/III rectal cancer who were recruited
from2003 to2005.Eligiblepatientswerecontacted1 to4monthsafter
diagnosis and asked to participate in a telephone survey and to con-
sent to medical record review, with separate follow-up QOL surveys
conducted 1 and 7 years after diagnosis.
Results: Two hundred thirty-nine patients with stage II/III
rectal cancer were included in this analysis. Younger age
( 65 v  65 years: odds ratio, 2.49; 95% CI, 1.33 to 4.65)
was significantly associated with increased odds of receiving
neoadjuvant or adjuvant chemoradiotherapy. The adjuvant
chemoradiotherapy group had significantly worse mean Euro-
Qol-5D (range, 0 to 1) and Short Form-12 physical health
component scores (standardized mean, 50) at 1-year fol-
low-up than the neoadjuvant chemoradiotherapy group (0.75
v 0.85; P  .002; 37.2 v 43.3; P  .01, respectively) and the
group that received only one or neither form of treatment (0.75
v 0.85; P  .02; 37.2 v 45.1; P  .008, respectively).
Conclusion: Neoadjuvant treatment may result in better
QOL and functional status 1 year after diagnosis. Further eval-
uation of patient and provider reasons for not pursuing neo-
adjuvant therapy is necessary to determine how and where to
target process improvement and/or education efforts to en-
sure that patients have access to recommended treatment
options.
Introduction
Since 1990, a multimodality approach of surgery and chemo-
radiotherapy has been the standard of care for stages II/III rectal
cancer.1 Subsequently, neoadjuvant chemoradiotherapy was
shown to improve local control and reduce toxicity in the Ger-
man Rectal Cancer Study Group trial that was published in
20042; these results persisted after a median follow-up of 11
years.3 Although neoadjuvant chemoradiotherapy is the Na-
tional Comprehensive Cancer Network (NCCN) guideline–
recommended treatment approach,4 many patients do not
receive neoadjuvant or even adjuvant chemoradiotherapy.
Analyses of SEER data demonstrate that the proportion of pa-
tients with stages II and III rectal cancer who do not receive any
radiotherapy is slowly decreasing,5,6 but approximately one quarter
of patients diagnosed in 2010 still did not receive radiotherapy.7
The reasons for non–guideline concordant care are unclear.5,6,8
Studies that were based on SEER data for those with stages II and
III rectal cancer found that patients who did not receive radiother-
apy were older compared with those who did receive it.5,6,9,10
Black patients are also less likely to receive radiotherapy compared
with white patients.9-11 Unfortunately, SEER data do not allow for
examination of patient preferences, comorbidities, adverse therapy
effects, and other clinical factors that may elucidate possible expla-
nations for nonreceipt of chemoradiotherapy.
Althoughneoadjuvantchemoradiotherapyhasbeendemonstrated
to decrease toxicity and local recurrence compared with adjuvant che-
moradiotherapy, few studies have examined long-term differences in
quality of life (QOL) between the two approaches.12,13 Neoadjuvant
or adjuvant chemoradiotherapy can increase the risk for long-term
bowel/anorectal, urinary, and sexual dysfunction.13-24 In this study,
we address these gaps in our understanding by using data from Can-
CORS (the Cancer Care Outcomes Research and Surveillance Con-
sortium). The two objectives of this study were to examine patient
characteristics associated with the receipt and sequence of therapy, and
to evaluate the impact of therapy receipt and sequence on long-term
QOL and functional status among disease-free survivors.
Methods
Study Population and Design
CanCORS is a geographically diverse population- and health
system–based cohort study that included 4,723 adults age 21
years or older with newly diagnosed, pathologically confirmed,
invasive colorectal cancer who were recruited between 2003
and 2005. Patients were recruited from four geographically
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based cancer registries in Northern California, Los Angeles
County, North Carolina, and Alabama, from five large
health maintenance organizations (HMOs) that are part of
the Cancer Research Network, and from five Veterans Af-
fairs (VA) hospitals.
As described previously,25 eligible patients from these sites
were contacted approximately 4 months after cancer diagnosis
and asked to participate in a baseline telephone survey, with
interview type (full, brief, surrogate interview for live patient,
surrogate interview for deceased patient) dependent on patient
status. Interviews included questions about sociodemographic
characteristics, treatments, providers, goals/beliefs/preferences
with regard to treatment options, symptoms, and quality of
life.26
Medical records were abstracted from 3 months before di-
agnosis through at least 15 months after diagnosis. The Can-
CORS medical record abstraction (MRA) database contains
information on tumor characteristics and the acute treatment
phase, including provider types visited, staging procedures, and
surgery, chemotherapy, and radiotherapy regimens.25-27 Med-
ical record information was also used to assign American Joint
Committee on Cancer collaborative stage28 and to determine
Adult Comorbidity Evaluation–2729 comorbidity indicators.
CanCORS participants were also surveyed approximately 1
and 7 years after diagnosis. Functional status was measured at
baseline and in both follow-up surveys using the Short Form-12
(SF-12).30,31 QOL was measured by the EuroQoL-5D (EQ-
5D) scale.32-34 Defecation problems such as frequency of bowel
movements, unintentional release of stools, difficulty or pain
with moving bowels, and blood with stools were assessed via a
Defecation Scale developed by CanCORS investigators.26 The
lower the Defecation Scale score, the more problems reported
by the participant (ie, higher scores correspond to better func-
tion).
Analyses included patients with stage II or III adenocarci-
noma of the rectum with no previous history of cancer, except
for nonmelanoma skin cancers. Stage was based on a hierarchy
of best available evidence with Collaborative Stage (calculated
American Joint Committee on Cancer stage based on medical
record–abstracted tumor size, extension, lymph nodes, and me-
tastases) at the top of the hierarchy. Pretreatment clinical stage
was generally used for patients who received neoadjuvant ther-
apy as opposed to pathologic staging at surgery. The algorithm
for determining stage is described in detail elsewhere.35 Those
with tumors at the rectosigmoid junction were excluded, given
that administration of chemotherapy and radiotherapy is not
included in guidelines for higher lesions. The study was ap-
proved by human subjects committees at all participating insti-
tutions.
Data Analysis
Patients were divided into two groups: first, those who received
neoadjuvant chemoradiotherapy or adjuvant chemoradiother-
apy; and second, those who received only chemotherapy or only
radiotherapy (regardless of when administered) or neither. 2
and Fisher’s exact tests were used to compare the groups on key
variables obtained from the CanCORS survey and MRA data-
base. Multivariable logistic regression was used to examine pa-
tient characteristics associated with the two groups described;
all variables listed in Table 1 and Appendix Table A1 (online
only) were considered for inclusion in the models. Variables
that were not significant predictors after adjustment for other
covariates (P  .10) were removed in a backward selection
process.
For QOL analyses, the study population was limited to pa-
tients who were alive and disease-free at 7 years postdiagnosis.
Group one was further stratified into patients who received
neoadjuvant chemoradiotherapy (as a proxy measure for at-
tempted guideline care) versus adjuvant chemoradiotherapy.
Patients receiving both neoadjuvant chemoradiotherapy as well
as adjuvant chemotherapy were placed in the neoadjuvant
group. Multivariable linear regression was used to determine
the relationship at baseline between the functional status/QOL
scores mentioned previously and candidate predictor variables
listed in Table 1 and Appendix Table A1. This set of candidate
predictors, plus the baseline value of the outcome variable, was
also used to model functional status/QOL measured in the 1-
and 7-year follow-up surveys. Treatment was considered a key
predictor and was not a candidate for removal in the backward
selection procedure, as were baseline scores for the 1- and 7-year
outcome measures. For all logistic regressions, patients were
excluded if they were missing information for any variable in-
cluded in that specific model. The minimum number of cova-
riates in any of the models was one, and the maximum number
was eight. All statistical analyses were performed in SAS soft-
ware (version 9.3; SAS Institute, Cary, NC) on version 12 of the
CanCORS surveys and MRA (version17 core data set).
Results
A total of 239 patients met the inclusion criteria for the objec-
tive 1 analysis. One hundred eighty-three patients (77%) re-
ceived either neoadjuvant or adjuvant chemoradiotherapy, and
56 (23%) received only one treatment modality or neither (Fig-
ure 1). Among those who received chemoradiotherapy, 119
(65%) received neoadjuvant chemoradiotherapy and 64 (35%)
received adjuvant chemoradiotherapy (Figure 1). Figure 1
shows the number who received each therapy and the sequence
in which therapy was received; more detailed information on
those receiving neoadjuvant versus adjuvant chemotherapy and
radiotherapy is described in the article by Charlton et al.8
Patient Characteristics Associated With Receipt
of Chemoradiotherapy
The characteristics of the two study groups are presented in
Table 1. Compared with the group that received only one or
neither treatment modality, higher proportions of the group
that received both (either neoadjuvantly or adjuvantly) were
younger than age 75 years, had received recommended mag-
netic resonance imaging of the pelvis or transrectal ultrasound
for locoregional staging, positron emission tomography and
carcinoembryonic antigen testing during the staging/pretreat-
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Table 1. Patient Demographic and Clinical Characteristics
Characteristic (N  239) Chemotherapy and Radiotherapy (n  183; % [No.]) Not Both/Neither* (n  56; % [No.]) P
Female sex 35 (64) 41 (23) .41
Lives alone 61 (112) 64 (36) .68
White race 62 (113) 61 (34) .89
Age group, years
 55 32 (59) 20 (11)  .01
55-64 32 (58) 25 (14)
65-74 21 (38) 16 (9)
 75 15 (28) 39 (22)
Insurance
Covered by at least one insurer/payer 83 (151) 81 (44) .72
None/NA/missing 17 (32) 19 (12)
Education
 12 years 46 (85) 50 (28) .64
 13 years 54 (98) 50 (28)
Source of case
HMO 64 (117) 71 (40) .18
Cancer registry 21 (39) 23 (13)
VA 15 (27) 5 (3)
Locoregional clinical staging
MRI or TRUS 34 (63) 18 (10) .02
PET 29 (53) 14 (8) .03
CEA 86 (158) 73 (41) .02
Stage III (v stage II) 54 (99) 59 (33) .52
Tumor size, mm
Median 48 47 .81
IQR 30-55 30-60
Sphincter status
Preserved 63 (115) 80 (45) .01
Removed 37 (68) 20 (11)
Chemotherapy (n  203)
Neoadjuvant 65 (119) 0 (0)  .01
Adjuvant 35 (64) 100 (20)
Radiotherapy (n  188)
Neoadjuvant 65 (119) 60 (3) .82
Adjuvant 35 (64) 40 (2)
Comorbidity
None 34 (62) 25 (14) .61
Mild 41 (75) 48 (27)
Moderate 17 (31) 20 (11)
Severe 8 (15) 7 (4)
Baseline survey type
Full 76 (139) 63 (35) .03
Brief 14 (25) 16 (9)
Surrogate, live 9 (17) 14 (8)
Surrogate, deceased 1 (2) 7 (4)
State of health rating
Baseline
Mean 68 71 .40
SD 22 22
continued on next page
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ment period, and underwent sphincter-preserving surgery. Al-
though both groups had similar self-reported health ratings at
the time of diagnosis, those who received chemoradiotherapy
had higher average ratings when asked about their general
health status 1 year before diagnosis. A significantly lower pro-
portion of the group that received chemoradiotherapy was de-
ceased at the time of the baseline survey compared with the
group that did not receive both (1% v 7%; P  .03; data not
Table 1. (continued)
Characteristic (N  239) Chemotherapy and Radiotherapy (n  183; % [No.]) Not Both/Neither* (n  56; % [No.]) P
1 year before
Mean 84 75 .02
SD 21 25
Current health state
Excellent/very good 39 (71) 41 (23) .05
Good 35 (64) 30 (17)
Fair/poor 23 (42) 16 (9)
Unknown/NA 3 (6) 13 (7)
Survival
Alive 1 year after diagnosis 94 (172) 88 (49) .22
Alive 7 years after diagnosis 56 (103) 48 (27) .29
Abbreviations: CEA, carcinoembryonic antigen; HMO, health maintenance organization; IQR, interquartile range; MRI, magnetic resonance imaging; NA, not applicable;
PET, positron emission tomography; SD, standard deviation; TRUS, transrectal ultrasound; VA, Veterans Affairs.
* Received chemotherapy only, radiotherapy only, or neither.
Patients with stages II and III rectal cancer in CanCORS database
(N = 326)
Completed quality of life portion of 7-year follow-up surveys*
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(n = 183; 77%)
Survived > 7 years
(n = 27; 48%)
Chemotherapy only, radiotherapy only, or neither (n = 56; 23%)
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)02 = n( ylno yparehtomehc tnavujdA  
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Survived > 7 years
(n = 70; 59%)
Survived > 7 years
(n = 33; 52%)
Baseline (n = 24)
1-year (n = 23)
7-year (n = 12)
Adjuvant chemotherapy
and radiotherapy only
(n = 64; 35%)
Neoadjuvant chemotherapy (n = 119; 65%)
 and radiotherapy
  Neoadjuvant chemotherapy and (n = 70)
    radiotherapy + adjuvant chemotherapy
  Neoadjuvant chemotherapy (n = 49)
    and radiotherapy only
Baseline (n = 63)
1-year (n = 62)
7-year (n = 26)
Baseline (n = 32)
1-year (n = 29)
7-year (n = 11)
Figure 1. Patient flow diagram for the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) patients with stages II and III rectal
cancer. * Reasons for missing quality-of-life (QOL) scores: baseline (BL): 10 patients had surrogates complete survey, and QOL scores were not
available from these surveys; one patient did not answer the QOL questions. 1-year follow-up: 10 refused; four could not be contacted; two did not
answer the QOL questions. 7-year follow-up: six patients had advanced disease so did not take the disease-free survivor survey; 33 refused; three
incapable of responding; 39 could not be contacted.
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shown). However, the difference in the proportions alive 1 year
after diagnosis was not significant (94% v 88%; P  .22).
A higher proportion of those who received only one treat-
ment modality or neither indicated that they had made the
decisions themselves (with little or no input from physicians)
on whether or not to have chemotherapy and/or radiotherapy,
whereas half of those who received chemoradiotherapy reported
making the decision to receive these treatments together with
their physician. A higher proportion of the group who received
chemoradiotherapy indicated that chemotherapy would likely
prolong their lives, help with their symptoms, and have adverse
effects, and that radiotherapy would likely cure their cancer,
prolong their lives, and help with their symptoms as compared
with those who received only one or neither treatment modality
(Table A1, online only).
Of those who did not receive chemotherapy, 44% reported
that no physician ever talked to them about having chemother-
apy. Similarly, 41% of those who did not receive radiotherapy
said that no physician ever talked to them about having radio-
therapy. On the basis of medical record abstraction, 20% of
those who did not receive chemotherapy visited a medical on-
cologist, and 33% of those who did not receive radiotherapy
visited a radiation oncologist (results not shown).
After considering all variables in Table 1 and Appendix Ta-
ble A1, results of multivariable analyses indicated younger age
( 65 years v  65 years: odds ratio, 2.49; 95% CI, 1.33 to
4.65) was significantly associated with increased odds of receiv-
ing chemoradiotherapy. Preservation of the sphincter was asso-
ciated with decreased odds of receiving chemoradiotherapy
(odds ratio, 0.34; 95% CI, 0.16 to 0.73, results not shown),
potentially as a result of surgeons being less likely to refer pa-
tients for neoadjuvant chemoradiotherapy when they had
higher tumors and sphincter preservation was possible without
the need to preoperatively reduce tumor bulk.
QOL Among Disease-Free Survivors
Of those who survived at least 7 years and completed the QOL
and functional status questions at baseline or 1-year follow-up
(n  130), 49 (38%) completed the 7-year disease-free fol-
low-up survey; six people who were contacted had advanced
disease and therefore took a different survey. There were no
significant differences in the demographic or clinical character-
istics between those who did and did not complete the 7-year
survey, although participants who completed the 7-year survey
were marginally more likely to have had at least some college
education (P  .06) and were enrolled onto the study via a
cancer registry versus the VA or an HMO (P  .07). We also
compared the characteristics of participants who survived at
least 7 years with those who did not. Those who survived at least
7 years were significantly younger than those who did not. They
also more frequently lived alone, and were enrolled onto the
study through an HMO (results not shown).
The adjusted EQ-5D, SF-12, and Defecation Scale scores by
time since diagnosis (ie, baseline, 1 year, 7 years) for patients
who received chemoradiotherapy compared with those who
received only one or neither treatment modality are presented
in Table 2. There were no significant differences in QOL or
functional status at any time point except for the SF-12 mental
health component score at baseline (ie, 1 to 4 months after
diagnosis); those receiving chemoradiotherapy had a signifi-
cantly lower score than those who received only one treatment
modality or neither (43.1 v 48.8; P  .04). The adjuvant che-
moradiotherapy group had significantly worse EQ-5D scores
than the neoadjuvant chemoradiotherapy group and the group
who received only one or neither treatment modality at 1-year
follow-up (0.75, 0.85, 0.85, respectively; P  .002, .02), with a
similar pattern seen for the SF-12 physical health component
score (37.2, 43.3, 45.1, respectively; P  .01, .008). There were
no significant differences between the three treatment groups in
the SF-12 mental health component score or Defecation Scale
at any time point.
Discussion
These results are among the first to illustrate the effects of rectal
cancer treatment approach across real-world settings among
patients of all ages and states of health, and across several regions
of the United States. Our analyses demonstrate that a substan-
tial proportion (23%) of CanCORS patients with stage II/III
rectal cancer did not receive chemoradiotherapy. In addition,
we found that functional status and QOL were significantly
lower 1 year after diagnosis among those who received adjuvant
chemoradiotherapy compared with those who received neoad-
juvant chemoradiotherapy and only one or neither treatment.
Although decreased risk of recurrence, toxicity, and permanent
colostomies has previously been demonstrated among patients
receiving neoadjuvant chemoradiotherapy,2,3 the finding that
the neoadjuvant therapy group had functional status and QOL
scores similar to those of the group that received chemotherapy
only, radiotherapy only, or neither may provide a more com-
pelling rationale for adherence to the recommended sequence,
given that the group receiving only one or neither therapy
would be expected to experience the least long-term effects from
treatment.
Our findings with respect to the proportion of patients re-
ceiving recommended therapy were consistent with previous
evaluations of SEER data,5,6,9 which found that 30% to 40% of
patients with stage II/III rectal cancer did not receive any radio-
therapy, and that younger age was associated with receipt of
radiotherapy. These studies included earlier years of data before
wider uptake of NCCN guidelines for neoadjuvant chemora-
diotherapy, which may explain why their estimates of radio-
therapy nonreceipt are somewhat higher. Of the group that
received only chemotherapy, only radiotherapy, or neither,
73% had no or mild comorbidities, 88% were still alive 1 year
after diagnosis, and almost no patients reported that they ex-
pected to die in less than 5 years. Therefore, it does not seem
that lack of therapy in most cases was simply a result of immi-
nent death or patients being too ill to receive chemotherapy
and/or radiotherapy. The association between nonsphincter-
preserving surgery and receipt of chemoradiotherapy may sug-
gest that some surgeons predominantly refer patients with
lower-lying tumors for chemoradiotherapy in an attempt to
Charlton et al
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save the sphincter, and do not consistently refer patients with
higher tumors.
More than 40% of patients who did not receive chemora-
diotherapy reported that no physician ever discussed the possi-
bility of chemotherapy or radiotherapy with them, and medical
record data confirmed that 70% to 80% did not visit an oncol-
ogist. It is possible that those who did not visit an oncologist
refused to engage in a discussion about these therapies or did
not recall that a different type of physician had spoken with
them about it. However, given the high percentage of patients
who did not have medical record data indicating a visit to an
oncologist, it is also possible that the ideal multidisciplinary
approach to treatment planning for patients with rectal cancer
was not executed in the majority of these patients who did not
receive chemotherapy and radiotherapy, and that no one fully
described the treatment options and benefits to these individu-
als. Among the 27 (48%) members of the group who did not
receive both chemotherapy and radiotherapy and survived at
least 7 years, it is likely that they would not have gained benefit
from additional neoadjuvant or adjuvant therapy. However, the
52% who did not survive that long may have benefitted. It is
not currently possible to precisely predict at diagnosis who will
and will not benefit from neoadjuvant chemoradiotherapy,
which is why NCCN guidelines recommend it for nearly all
patients with stage II/III disease.
It should also be noted that a significantly higher percentage
of patients not receiving chemoradiotherapy reported that they
had made the decision concerning whether or not to receive
therapy, as opposed to making the decision together with their
physician or their physician alone making the decision. It is
possible that this is indicative of strong patient preference and
deference to patient autonomy on the part of the physician, or
alternatively, may indicate ineffective physician communica-
tion regarding the risk/benefit ratio for these treatments and/or
a lack of data clearly indicating their benefit.
Although the results indicated that there was no difference in
QOL at any time point between those who received chemora-
diotherapy and those who did not, except for the SF-12 mental
health component score at baseline, the stratified analysis by
chemotherapy-radiotherapy-surgery sequence demonstrated
that those receiving adjuvant chemoradiotherapy had lower
EQ-5D and SF-12 physical health component scores 1 year
after diagnosis after adjusting for baseline scores and other co-
variates. Statistically significant differences also fell within pre-
viously reported minimal clinically important difference ranges
for the EQ-5D and SF-12.36-40 There were no other significant
differences among groups at the follow-up time points. Two
other long-term follow-up studies found that patients receiving
neoadjuvant radiotherapy reported fewer bowel movements
compared with patients receiving adjuvant radiotherapy,12,13
but did not find differences in overall functional status or
QOL.13 It is possible that the main benefits of neoadjuvant
chemoradiotherapy compared with adjuvant chemoradiother-
apy occur in the short term, and that over time, the effects of
any treatment for rectal cancer on QOL become more similar.
A potential limitation of this study is that self-reported in-
formation may have been collected before oncologist visits and
treatment discussions with other providers. However, the fact
that both medical record and self-report data could be used and
compared for variables such as oncologist visits was a strength of
Table 2. Adjusted Functional Status, QOL, and Defecation Scale Scores by Treatment and Time Since Diagnosis Among Those Who












EQ-5D 0.85 0.79 0.64 0.88 0.82 0.72
SF-12
Physical health 36.2 40.5 37.9 39.0 44.5 37.9
Mental health 43.1† 51.1 51.8 48.8† 54.9 52.2
Defecation Scale‡ 66.9 71.5 68.8 73.7 68.4 75.8


























EQ-5D 0.81 0.85† 0.66 0.78 0.75† 0.61 0.83 0.85† 0.72
SF-12
Physical health 35.4 43.3† 37.9 36.9 37.2† 34.1 40.0 45.1† 36.5
Mental health 46.7 48.5 52.0 44.9 46.5 51.2 49.9 49.0 52.2
Defecation Scale 64.9 70.3 58.2 60.1 73.0 80.1 72.5 68.4 75.2
Abbreviations: BL, baseline; EQ-5D, EuroQol-5D; QOL, quality of life; SF-12, Short Form-12.
* All factors in Table 1 and Appendix Table A1 were candidates for the models, plus corresponding baseline scores.
† Significant difference between groups, P  .05.
‡ Defecation Scale only administered to patients who received sphincter-preserving surgery; n  57 responded at baseline, n  70 at 1 year, and n  32 at 7-year follow-up.
Long-Term QOL in CanCORS Patients With Stage II/III Rectal Cancer
JULY 2015 • jop.ascopubs.org e481Copyright © 2015 by American Society of Clinical Oncology
this study. We also do not have information on whether pa-
tients were discussed in a Tumor Board or other multidisci-
plinary setting. Another potential limitation is the possibility of
confounding by unmeasured characteristics that may have dif-
fered between treatment groups such as exact location of the
tumor, hospital type/size, specialty of the surgeon, and other
provider characteristics. Finally, small sample size, especially at
the point of 7 years after diagnosis as a result of loss to follow-up
or death, reduced statistical power for some subgroup analyses,
and we were unable to stratify on the basis of specific chemo-
therapy drugs, chemotherapy and radiotherapy dosage, and ex-
act timing of administration to determine complete compliance
with guidelines.
In conclusion, the majority of patients with stage II and III
rectal cancer received chemoradiotherapy, but a substantial
proportion of patients did not. It is possible that patient pref-
erences or proximal tumor location explain some of this varia-
tion, but on the basis of the finding that patients often reported
not being told of these therapies, it is questionable whether or
not many patients were given the opportunity to learn more
about treatment options directly from oncologists. Among pa-
tients who did receive chemoradiotherapy, those who received
guideline-recommended neoadjuvant therapy had the best
QOL and physical health scores 1 year later. Further evaluation
of patient and provider reasons for not pursuing recommended
neoadjuvant chemoradiotherapy is necessary to determine how
and where to target process improvements and education to
ensure that patients have access to recommended treatments.
More immediately, ensuring that patients have an opportunity
to have a thorough, individualized discussion regarding chemo-
radiotherapy before surgery would also likely increase receipt of
guideline-concordant care.
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Appendix




(n  183; %, [No.])
Not Both/
Neither*
(n  56; %, [No.]) P
Patient role in decision making about therapies†‡§ (4 missing responses; 40 not asked¶)
Decision to have chemotherapy
Patient made decision 32 (52) 52 (17) .02
Patient made decision together with physician 50 (81) 33 (11)
Physicians made decision 17 (27) 15 (5)
Do not know 1 (2) 0 (0)
Decision to have radiotherapy
Patient made decision 35 (58) 47 (14)  .01
Patient made decision together with physician 50 (83) 30 (9)
Physicians made decision 12 (19) 17 (5)
Do not know 3 (5) 7 (2)
Patient beliefs about therapies†‡§ (chemotherapy: 46 not asked¶; 4 missing;
radiotherapy: 45 not asked¶; 3 missing )
Chemotherapy (“very likely” or “somewhat likely”)
Would likely cure their cancer 69 (111) 56 (15) .24
Would likely prolong their life 88 (142) 59 (16)  .01
Would likely help with their symptoms 77 (109) 50 (12) .02
Would likely have side effects 86 (140) 67 (18) .03
Radiotherapy (“very likely” or “somewhat likely”)
Would likely cure their cancer 61 (101) 32 (8) .03
Would likely prolong their life 80 (133) 36 (9)  .01
Would likely help with their symptoms 70 (105) 41 (9) .05
Would likely have side effects 71 (118) 52 (13) .06
Role patient generally prefers to play in decision making and role family played†§ (5 missing)
Preferred role
Patient make decision on his/her own 32 (49) 39 (16) .82
Make the decision together with physician 58 (89) 51 (21)
Physicians make the decision 10 (15) 10 (4)
Role family played
Patient made decision 45 (68) 50 (19) .81
Make the decision together with family 53 (81) 47 (18)
Family made decision 2 (3) 3 (1)
Preferences regarding extension of life†§ (5 missing)
Extension of life v pain and discomfort
Prefers treatment that extends life as much as possible, even if it means
having more pain/discomfort
53 (82) 32 (13) .09
Prefers treatment that focuses on relieving pain as much as possible, even
if it means not living as long
35 (54) 51 (21)
Refused to answer/do not know 12 (19) 17 (7)
Extension of life v cost of treatment
Prefers treatment that extends life as much as possible, even if it means
using up financial resources
63 (97) 49 (20) .25
Prefers treatment that costs less, even if means not living as long 26 (41) 32 (13)
Refused to answer/do not know 11 (17) 19 (8)
continued on next page
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(n  183; %, [No.])
Not Both/
Neither*
(n  56; %, [No.]) P
Expected time to live, fatalism beliefs, and concerns about treatment†
Expected time to live
Less than 5 years 4 (6) 6 (2) .88
At least 5 years 62 (84) 64 (21)
In God’s hands/do not know 34 (46) 30 (10)
Fatalism beliefs (“strongly agree” or “agree”)
When bad things happen, we are not supposed to know
why, we are just supposed to accept them
40 (57) 53 (18) .34
People die when it is their time, and nothing can change it 62 (87) 56 (19) .30
Everything that happens is a part of God’s plan 76 (107) 71 (24) .50
If bad things happen, it is because they were meant to be 44 (62) 44 (15) .74
Treatment concerns (“very worried” or “somewhat worried”) about:
Adverse effects from treatment 63 (87) 53 (18) .26
Cost of treatment 21 (29) 26 (9) .81
Taking time away from family 33 (46) 41 (14) .80
Taking time away from work 32 (44) 44 (15) .76
Transportation to treatment 13 (18) 14 (5) .45
* Received chemotherapy only, radiotherapy only, or neither.
† Full survey.
‡ Brief survey.
§ Survey of surrogate (live patient).
 Survey of surrogate (deceased patient).
¶ Items not asked of those reporting that no one ever talked to them about chemotherapy/radiotherapy, or that they were told not to have it.
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